WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL

Immunoglobulin A (IgA) nephropathy (IgAN) is most prevalent and likely to progress to kidney failure in individuals of East Asian ancestry, followed by individuals of White race and ethnicity. Nefecon, a novel, oral, targeted-release budesonide formulation, is specifically designed to treat IgAN by inhibiting galactose-deficient (Gd-IgA1) formation in the Peyer's patch–rich distal ileum. Part A of the phase III NefIgArd clinical trial reported significant reductions in urine protein–creatinine ratio (UPCR) and significant benefit on estimated glomerular filtration rate (eGFR) with Nefecon versus placebo over 9 months of treatment followed by 3 months off treatment (Barratt J, et al.